IP Library Granted Patent US 9,914,692
Granted Patent B2
US 9,914,692 · App. 15/164,126 · Granted Mar 13, 2018

Procedure for the preparation of 4-phenyl butyrate and uses thereof

Inventors: Huai-Chueh Chang (Tower Lakes, IL); Steven S. Pfeiffer (Camarillo, CA); Vasilios H. Iskos (Chicago, IL); Maki Uragami (Bethlehem, PA); Steven Weissman (Short Hills, NJ); Andrew Thompson (Mountainside, NJ)
Assignee: Horizon Therapeutics, LLC
C07C69/616C07C51/29C07C57/30C07C67/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,914,692
App. No.
15/164,126
Granted
Mar 13, 2018
Kind
B2
Abstract

Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.

Claims (21)

1. A process for preparing 4-phenyl-1-butyric acid, comprising:

reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite.

2. The process of claim 1 , wherein said reacting 4-phenyl-1-butanol with sodium chlorite, the nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer comprises sequentially adding sodium chlorite and sodium hypochlorite to a mixture of 4-phenyl-1-butanol and the nitroxyl radical catalyst in an organic solvent and a phosphate buffer.

3. The process of claim 1 , wherein the nitroxyl radical catalyst is chosen from a TEMPO catalyst and an AZADO catalyst or a mixture thereof.

4. The process of claim 3 , wherein the TEMPO catalyst is chosen from TEMPO (a free radical of 2,2,6,6-tetramethyl-1-piperidinyloxy), 4-MeO-TEMPO (4-methoxy-2,2,6,6-tetramethylpiperidine-1-oxyl); 4-acetoamido-TEMPO (4-acetamido-2,2,6,6-tetramethylpiperidine-1-oxyl), and 4-hydroxy-TEMPO (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl).

5. The process of claim 3 , wherein the TEMPO catalyst is polymer-supported.

6. The process of claim 3 , wherein the AZADO catalyst is chosen from 2-azaadamantane N-oxyl (AZADO), 1-methyl-2-azaadamantane-N-oxyl (1-Me-AZADO), and 9-azanoradamantane N-oxyl (Nor-AZADO).

7. The process of claim 3 , wherein the nitroxyl radical catalyst is 9-azabicyclo[3.3.1]nonane N-oxyl (ABNO).

8. The process of claim 1 , wherein the organic solvent is selected from acetonitrile, tetrahydrofuran, 2-methyltetrahydrofuran, diethyl ether, methyl tert-butyl ether, dimethoxyethane, 2-methoxyethyl ether (diglyme), triethylene glycol dimethyl ether (triglyme), toluene, benzene, hexane, pentane, dioxane, and mixtures thereof.

9. The process of claim 8 , wherein the organic solvent is acetonitrile.

10. The process of claim 1 , wherein the phosphate buffer comprises an aqueous solution of potassium phosphate monobasic and potassium phosphate dibasic.

11. The process of claim 10 , wherein potassium phosphate monobasic and potassium phosphate dibasic are each used in amounts of about 0.5 equivalent to about 1.5 equivalents.

12. The process of claim 1 , wherein the amount of the nitroxyl radical catalyst used is about 1.0 to about 50.0 mol percent.

13. The process of claim 12 , wherein the amount of the nitroxyl radical catalyst used is about 5.0 to 10.0 mol percent.

14. The process of claim 12 , wherein the amount of the nitroxyl radical catalyst used is about 7.0 mol percent.

15. The process of claim 1 , wherein the amount of sodium chlorite used is about 1 equivalent to about 3 equivalents.

16. The process of claim 15 , wherein the amount of sodium chlorite used is about 1.5 equivalent to about 2 equivalents.

17. The process of claim 16 , wherein the amount of sodium chlorite used is about 1.7 equivalents.

18. The process of claim 1 , wherein the sodium sulfite is aqueous sodium sulfite.

19. The process of claim 1 , wherein the sodium sulfite is solid sodium sulfite.

20. The process of claim 1 , wherein the amount of sodium sulfite used is about 1 to about 3 equivalents.

Assignments (7)
MERGER AND CHANGE OF NAME Recorded Dec 21, 2023
From: HORIZON THERAPEUTICS, LLC; HORIZON ORPHAN LLC
To: HORIZON THERAPEUTICS U.S. HOLDING LLC
Reel/Frame 065928/0608 →
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.); HZNP LIMITED; HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)
Reel/Frame 065154/0075 →
SECURITY AGREEMENT Recorded Oct 24, 2018
From: HORIZON PHARMA RHEUMATOLOGY LLC; HZNP LIMITED; HORIZON THERAPEUTICS, LLC
To: CITIBANK, N.A.
Reel/Frame 047720/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2017
From: CHANG, HUAI-CHUEH; PFEIFFER, STEVEN S.; ISKOS, VASILIOS H.; URAGAMI, MAKI; WEISSMAN, STEVEN; THOMPSON, ANDREW
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 043004/0799 →
CORRECTIVE ASSIGNMENT TO CORRECT THE TWO PATENT NUMBERS PREVIOUSLY RECORDED AT REEL: 039640 FRAME: 0886. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Apr 17, 2017
From: HORIZON THERAPEUTICS INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 043156/0175 →
CHANGE OF NAME Recorded Aug 26, 2016
From: HORIZON THERAPEUTICS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 039640/0886 →
CHANGE OF NAME Recorded Aug 9, 2016
From: HORIZON THERAPEUITCS, INC.
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 039633/0851 →
Continuity (1)
Related Publication 20170342018A1 · Nov 30, 2017